文献速递骨软组织肉瘤与黑色素瘤

III期黑色素瘤的手术范围:多大程度是合适的?

The extent of surgery for stage III melanoma: how much is appropriate?
PubMed 文献 · Lancet Oncol · 2019-01-01

综述回顾了自1892年以来淋巴结清扫术对黑色素瘤生存影响的试验证据,指出前哨淋巴结阳性患者完成性淋巴结清扫与观察相比未显示生存获益,而辅助免疫治疗和靶向治疗已改善生存结局,III期黑色素瘤手术类型和范围正变得更加个体化。

要点

  • 两项随机对照试验未能证明前哨淋巴结阳性患者完成性淋巴结清扫较淋巴结观察改善生存。
  • 前哨淋巴结转移灶较大(>1 mm)的患者可能从观察中获益更多,可考虑辅助全身治疗替代完整清扫。
  • 常规对前哨淋巴结阳性疾病进行完成性淋巴结清扫应重新考虑,现有临床指南正在修订中。

核心结论

  • 尽管前哨淋巴结阳性或阴性患者完成性淋巴结清扫未显示生存获益,但有效辅助治疗的引入将使前哨淋巴结分期应用增加。
  • 常规对前哨淋巴结阳性疾病进行完成性淋巴结清扫应重新考虑,现有临床指南正在修订中。
  • 对于可触及(宏观)淋巴结疾病,若能准确预测反应且研究显示完全缓解患者可安全放弃淋巴结清扫,手术类型和范围可减少。
  • 总体而言,III期黑色素瘤合适的手术类型和范围正在变化并变得更加个体化。

研究设计与样本

  • 综述回顾了自1892年首次记录淋巴结清扫以来调查该手术对黑色素瘤患者生存潜在影响的众多试验。

主要发现

  • 两项随机对照试验未能证明前哨淋巴结阳性患者完成性淋巴结清扫较淋巴结观察改善生存。
  • 前哨淋巴结转移灶较大(>1 mm)的患者可能从观察中获益更多,而非从清扫中获益更多,并可能考虑辅助全身治疗替代完整清扫。
  • 大剂量伊匹木单抗辅助免疫治疗改善了总生存,而纳武利尤单抗和帕博利珠单抗治疗改善了无复发生存且安全性更高。
  • 达拉非尼联合曲美替尼辅助靶向治疗改善了BRAFV600E和BRAFV600K突变黑色素瘤的生存结局。
  • 三项新辅助试验均显示短程伊匹木单抗联合纳武利尤单抗治疗后高缓解率(包括完全缓解),迄今无复发,但随访仍短。

临床怎么用

  • 常规对前哨淋巴结阳性疾病进行完成性淋巴结清扫应重新考虑。
  • 前哨淋巴结转移灶较大(>1 mm)的患者可能考虑辅助全身治疗替代完整清扫。
  • 对于可触及(宏观)淋巴结疾病,若能准确预测反应且研究显示完全缓解患者可安全放弃淋巴结清扫,手术类型和范围可减少。

局限性

  • 新辅助试验随访仍短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Since the first documented lymph node dissection in 1892, many trials have investigated the potential effect of this surgical procedure on survival in patients with melanoma. Two randomised controlled trials were unable to demonstrate improved survival with completion lymph node dissection versus nodal observation in patients with sentinel node-positive disease, although patients with larger sentinel node metastases (>1 mm) might benefit more from observation than from dissection, and could potentially be considered for adjuvant systemic therapy instead of complete dissection. Adjuvant immunotherapy with high-dose ipilimumab has led to improvements in overall survival, whereas therapy with nivolumab and pembrolizumab has improved relapse-free survival with greater safety. Furthermore, adjuvant-targeted therapy with dabrafenib and trametinib has improved survival outcomes in BRAFV600E and BRAFV600K-mutated melanomas. Three neoadjuvant trials have all shown high response rates, including complete responses, after short-term combination therapy with ipilimumab and nivolumab with no recurrences so far, although follow-up is still short. Despite the absence of a survival benefit with completion lymph node dissection in patients with sentinel node-positive or negative disease, the use of sentinel node staging will increase because of the introduction of effective adjuvant therapies. However, routine completion lymph node dissection for sentinel node-positive disease should be reconsidered. Accordingly, existing clinical guidelines are currently being revised. For palpable (macroscopic) nodal disease, the type and extent of surgery could be reduced if the index node can accurately predict the response and if studies show that lymph node dissection can be safely foregone in patients with a complete response. Overall, the appropriate type and extent of surgery for stage III melanoma is changing and becoming more personalised.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Franke V, van Akkooi ACJ. The extent of surgery for stage III melanoma: how much is appropriate? Lancet Oncol. 2019. PMID: 30842060. doi:10.1016/S1470-2045(19)30099-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。